The development of a gut-specific immune response to an oral antigen is dependent on α4β7 mediated lymphocyte trafficking

Autor: Allison L Sang, Naresh S Redhu, Dooyoung Lee, Fyonn Dhang, Raegan Bonesteel, Sarah St. Gelais, Cheng Zhong, Dan Cui, Bryce Harrison, Dawn Troast, Matthew G Bursavich, Blaise Lippa, Bruce N Rogers, Adrian S Ray, Jamie Wong
Rok vydání: 2022
Předmět:
Zdroj: The Journal of Immunology. 208:105.06-105.06
ISSN: 1550-6606
0022-1767
Popis: Objective Vedolizumab has been shown to reduce the antibody response to an oral cholera, but not intramuscular hepatitis B vaccine in healthy subjects (Wyant, Gut 2015). The generation of an immune response to an oral antigen (Ag) begins at inductive sites such as Peyer’s patches (PP) followed by cell migration to effector sites in the gut. The integrin α4β7 is known to play a major role in cell trafficking to gut-associated lymphoid tissues. This study assessed whether MT-102, a potent and selective small molecule α4β7 inhibitor has similar effects on immunizations to those reported in the clinic for vedolizumab. Methods An in vivo immunization model system was established to determine the effects of MT-102, dosed via osmotic minipump, on the development of a gut-specific immune response. Mice were orally immunized with cholera toxin (CTX), and anti-CTX antibodies were quantified in fecal and plasma samples. The impact of MT-102 on lymphocytes within the PP of immunized mice was determined by flow cytometry. Results MT-102 delayed the production of anti-CTX IgA and IgG antibodies as measured in fecal samples without perturbing total gut IgA levels. Furthermore, MT-102 also inhibited the levels of Ag-specific antibodies in the plasma following repeated CTX oral immunizations. Blocking α4β7 induced a decrease in the frequency of B cells in the PP of treated mice compared to the control group. Conclusion α4β7-specific inhibitor, MT-102, effectively diminished the mucosal antibody response to an orally delivered Ag in mice. These results are consistent with what has been reported clinically in vedolizumab-treated subjects and thus establishes that potent small molecule inhibitors of α4β7 can replicate the pharmacology of an antibody.
Databáze: OpenAIRE
Externí odkaz: